NCM · Biotechnology

BCAB (BCAB) Stock

$1.74 +0.00% NCM: BCAB Healthcare

Valuation

MetricValue
Price$1.74
Market Cap$2.88M
P/E Ratio-0.12
P/B Ratio-0.14
P/S Ratio0.61
EPS (TTM)$-50.50
52-Week High$71.50
52-Week Low$1.74
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE89.25%
ROA-330.89%
ROCE274.64%
Gross Margin-2950.00%
Operating Margin-2950.00%
Net Margin-370.05%
Debt/Equity-0.16
Current Ratio0.36

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$11.0M$2.0M
Operating Profit$-96.0M$-108.0M$-130.0M$-74.0M$-59.0M
Net Profit$-95.0M$-105.0M$-123.0M$-70.0M$-60.0M
EPS$-138.00$-137.00$-129.00$-72.00$-50.50
Op Margin-38576.0%——-672.2%-2965.3%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$254.0M$226.0M$120.0M$52.0M$14.0M
Total Liabilities$44.0M$45.0M$49.0M$38.0M$50.0M
Cash$245.0M$216.0M$111.0M$49.0M$7.0M
Borrowings$5.0M$4.0M$2.0M$1.0M$6.0M

Latest News

Context Therapeutics Secures Full Rights to CT-202 Under Revised BioAtla Deal MT Newswires · May 18, 2026 Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202 GlobeNewswire · May 18, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-62.0M$-90.0M$-104.0M$-72.0M$-48.0M
Investing Cash Flow$-2.0M$-1.0M$0$0$0
Financing Cash Flow$-2.0M$0$0$0$-1.0M
Net Cash Flow$6.0M$-29.0M$-104.0M$-62.0M$-42.0M
Free Cash Flow$-63.0M$-91.0M$-104.0M$-72.0M$-48.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.33
FCF Yield-453.51%
Quick Ratio0.20
Interest Coverage0.00
Return 1Y-78.38%
Return 3Y-96.84%
Return 5Y-99.78%

Ownership

Insiders Held5.46%
Institutions Held22.50%
Institutions Float Held23.80%
Institutional HolderSharesReport Date
Marshall Wace LLP277,6302026-03-31
Acorn Capital Advisors, LLC 108,1272026-03-31
Millennium Management Llc55,1332026-03-31
Vanguard Capital Management LLC32,9852026-03-31
Acadian Asset Management. LLC24,6782026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ANVSAnnovis Bio, Inc. $1.21 +3.42% -0.67 $51.48M 0.00%
BTAI $0.07 +0.00% -0.02 $2.28M 0.00%
CELUCelularity Inc. $1.56 +6.85% -0.51 $45.16M 0.00%
EVAXEvaxion Biotech A/S $3.05 +0.66% -1.99 $19.27M 0.00%
GBIOGeneration Bio Co. $5.34 +0.00% -0.87 $35.98M 0.00%

About BCAB

BCAB is led by CEO Jay Short, employs 61 people, headquartered in US, publicly traded since 2020.

BCAB stock trades at $1.74 with a market capitalization of $2.88M. The stock is valued at a price-to-earnings (P/E) ratio of -0.12, price-to-book of -0.14, price-to-sales of 0.61. Over the past 52 weeks the stock has ranged between $1.74 and $71.50, and currently trades 97.6% below its 52-week high.

On profitability, BCAB generates a return on equity (ROE) of 89.25% — well above the market average, a sign of a high-quality business, return on capital employed of 274.64%, an operating margin of -2950.00%, a net profit margin of -370.05%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides